No side effects were found in COVID-19 antiviral Favipiravir: Glenmark

The drug manufacturer Glenmark, on September 15, announced that it had found no new adverse effects in the post marketing surveillance (PMS) study conducted on Favipiravir (FabiFlu) in more than 1,000 COVID-19 patients. The reported side effects are in line with the well-known safety profile of the drug, the company said.Glenmark also said that the …

No side effects were found in COVID-19 antiviral Favipiravir: Glenmark Read More »